| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Class | GHRH analog (modified GRF 1-29) | Selective ghrelin-receptor agonist |
| CAS Number | 863288-34-0 | 170851-70-4 |
| Molecular Weight | 3,367.8 g/mol | 711.85 g/mol |
| Research note | Stimulates GH release via GHRH pathway | Selective GH release, minimal prolactin/cortisol |
Two pathways, one axis. CJC-1295 is a GHRH-receptor agonist, while Ipamorelin agonizes the ghrelin receptor (GHS-R1a). Because growth-hormone secretion is regulated by both pathways, the two are studied together to investigate the combined GHRH + ghrelin signaling on the GH axis.
Selectivity. Ipamorelin is noted in the research literature for its selectivity — minimal effect on prolactin, cortisol, and ACTH — making it a clean tool for isolating ghrelin-receptor effects.
View both compounds
Full mechanism, specifications, and certificates of analysis for each compound.
Frequently asked questions
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH-receptor agonist, while Ipamorelin agonizes the ghrelin receptor (GHS-R1a). They target two different receptors on the growth-hormone axis, which is why they are studied together. Both are Research Use Only.
Why are CJC-1295 and Ipamorelin used together in research?
Because they act on complementary receptors (GHRH receptor and ghrelin receptor), researchers pair them to study combined signaling on the growth-hormone axis.